Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $84.2 million.

  • Nurix Therapeutics' Shares Outstanding (Diluted Average) rose 15.64% to $84.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $84.2 million, marking a year-over-year increase of 15.64%. This contributed to the annual value of $67.1 million for FY2024, which is 23.52% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Shares Outstanding (Diluted Average) of $84.2 million as of Q3 2025, which was up 0.33% from $83.9 million recorded in Q2 2025.
  • Nurix Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $84.2 million for Q3 2025, and its period low was $42.9 million during Q4 2021.
  • For the 3-year period, Nurix Therapeutics' Shares Outstanding (Diluted Average) averaged around $66.0 million, with its median value being $62.4 million (2024).
  • Data for Nurix Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 52.20% (in 2025) over the last 5 years.
  • Nurix Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $42.9 million in 2021, then rose by 13.32% to $48.6 million in 2022, then increased by 11.79% to $54.3 million in 2023, then rose by 23.52% to $67.1 million in 2024, then grew by 15.64% to $84.2 million in 2025.
  • Its last three reported values are $84.2 million in Q3 2025, $83.9 million for Q2 2025, and $83.6 million during Q1 2025.